vebreltinib (APL-101)

News alerts, weekly reports and conference planners

Company:

Apollomics, Avistone Biotech, LaunXP Biomedical

Drug class:

c-MET inhibitor

Related drugs:

‹

›

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	APL-101 Sensitive: A1 - Approval APL-101 Sensitive : A1	APL-101 Sensitive: A1 - Approval APL-101 Sensitive : A1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2

Associations
(2)